CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Prone PositioningWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2333 Standard of care. Wiki 0.71
drug2376 Supine Positioning Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D012128 Respiratory Distress Syndrome, Adult NIH 0.06
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials


1 Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE

Prone positioning (PP) is an effective first-line intervention to treat moderate-severe acute respiratory distress syndrome (ARDS) patients receiving invasive mechanical ventilation, as it improves gas exchanges and lowers mortality.The use of PP in awake self-ventilating patients with (e.g. COVID-19 induced) ARDS could improve gas exchange and reduce the need for invasive mechanical ventilation, but has not been studied outside of case series.The investigators will conduct a randomized controlled study of patients with COVID-19 induced respiratory failure to determine if prone positioning reduces the need for mechanical ventilation compared to standard management.

NCT04347941 ARDS, Human Mechanical Ventilation Complication COVID19 Procedure: Prone Positioning Procedure: Standard of care.
MeSH:Respiratory Insufficiency Respiratory Distress Syndrome, Adult

Primary Outcomes

Description: A measure of effect of awake prone positioning in reducing requirement for invasive mechanical ventilation.

Measure: The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.

Time: Up to 28 days post randomisation

Secondary Outcomes

Description: Total time spent in prone and supine position as recorded by nurse

Measure: Length of time tolerating prone positioning

Time: Daily during intervention up to 28 days post randomisation

Description: Measure of change in oxygenation before intervention

Measure: PaO2/FiO2 measured before prone positioning

Time: Immediately before intervention

Description: Measure of change in oxygenation following intervention

Measure: PaO2/FiO2 ratio after 1 hours of prone positioning

Time: During intervention

Description: Measure of change in oxygenation using pulse oximetry before intervention where ABG not available

Measure: SpO2/FiO2 ratio measured before prone positioning

Time: Immediately before intervention

Description: Measure of change in oxygenation before intervention where ABG not available

Measure: SpO2/FiO2 ratio after 1 hours of prone positioning

Time: During Intervention

Description: Escalation of ventilatory support

Measure: Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc)

Time: Up to 28 days post randomisation

Description: Measure of work of breathing in COVID-19 based on Oxygen Delivery Device, Oxygen Saturation and respiratory rate and accessory muscle use with 0-3 Mild, 4-6 Moderate and 7-10 Severe

Measure: Work of breathing assessment (Respiratory distress scale)

Time: Immediately before and during intervention

Description: Substudy examining use of bioimpedance as a surrogate measure of lung edema following prone positioning

Measure: Changes in bioimpedance measures of lung edema in patients in PP

Time: During intervention

Description: Rescue awake prone positioning in control patients in response to hypoxia

Measure: Use of awake prone positioning as a rescue intervention in control patients

Time: Up to 28 days post randomisation

2 Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol

A pilot study to investigate the effects of the prone positioning (PP) on hospital patients diagnosed with COVID-19 pneumonia. Investigators that early self-proning may prevent intubation and improve mortality in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). Up to 100 participants with a primary diagnosis of confirmed COVID-19 pneumonia will be enrolled to the study. All participants will be screened and those that meet inclusion and exclusion criteria will be enrolled to one of two groups: one with prone positioning (on the belly) and the other with standard supine positioning (on the back). The patient and nursing staff will monitor times spent in various positions. Outcome measures include incidence of intubation, max oxygen requirements, length of hospital stay, ventilator-free days, worsening of oxygenation saturation, and mortality.

NCT04424797 COVID-19 Other: Prone Positioning Other: Supine Positioning
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Incidence of intubation

Measure: Incidence of intubation

Time: Through study completion, an average of 6 days

Secondary Outcomes

Description: Measure of maximum oxygen requirements

Measure: Maximum oxygen requirement

Time: Through study completion, an average of 6 days

Description: Measured in days of hospitalization

Measure: Length of Stay

Time: Through study completion, an average of 6 days

Description: Measured in days not on a ventilator

Measure: Ventilator-free days

Time: Through study completion, an average of 6 days

Description: Whether or not the participant met treatment failure descriptions

Measure: Treatment failure of prone positioning due to worsening SpO2 status while prone

Time: Through study completion, an average of 6 days

Description: Whether or not the participant died while hospitalized

Measure: Mortality

Time: Through study completion, an average of 6 days


Related HPO nodes (Using clinical trials)